Johnson & Johnson (JNJ) Long-Term Debt Repayments (2009 - 2024)
Johnson & Johnson's (JNJ) quarterly Long-Term Debt Repayments came in at $1.0 million in Q1 2024, down 99.8% year-on-year from $500.0 million in Q2 2023, and up 100.17% quarter-over-quarter from -$582.0 million in Q4 2023.
Johnson & Johnson (JNJ) Long-Term Debt Repayments (2009 - 2024) Analysis & Trends
Johnson & Johnson has disclosed Long-Term Debt Repayments across 16 years of filings, most recently posting $1.0 million for Q1 2024.
- Long-Term Debt Repayments for Q1 2024 came in at $1.0 million, down 99.8% year-over-year; the trailing twelve-month figure through Mar 2024 was $601.0 million (down 78.65% YoY), and the FY2025 annual result was $1.8 billion, up 20.92% from the prior year.
- Long-Term Debt Repayments came in at $1.0 million for Q1 2024 at Johnson & Johnson, up from -$582.0 million in the prior quarter.
- In the past five years, Long-Term Debt Repayments ranged from a high of $2.1 billion in Q2 2022 to a low of -$582.0 million in Q4 2023.
- The 5-year median for Long-Term Debt Repayments is $500.0 million (2023), against an average of $529.4 million.
- Across the five-year window, Long-Term Debt Repayments jumped 18266.67% in 2020 and plunged 185.34% in 2023, its largest moves.
- Johnson & Johnson's Long-Term Debt Repayments stood at $551.0 million in 2020, then plunged by 99.82% to $1.0 million in 2021, then changed by 0.0% to $1.0 million in 2022, then tumbled by 58300.0% to -$582.0 million in 2023, then surged by 100.17% to $1.0 million in 2024.
- The last three Long-Term Debt Repayments figures came in at $1.0 million (Q1 2024), -$582.0 million (Q4 2023), and $500.0 million (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 750.00 Mn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | - |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | - |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 1.14 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 833.00 Mn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 2.77 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 500.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 1.00 Mn |
| Mar 31, 2024 | 1.00 Mn |
| Dec 31, 2023 | -582.00 Mn |
| Dec 31, 2023 | -582.00 Mn |
| Apr 2, 2023 | 500.00 Mn |
| Apr 2, 2023 | 500.00 Mn |
| Jan 1, 2023 | 682.00 Mn |
| Jan 1, 2023 | 682.00 Mn |
| Oct 2, 2022 | 1.00 Mn |
| Oct 2, 2022 | 1.00 Mn |
| Jul 3, 2022 | 1.63 Bn |
| Jul 3, 2022 | 1.63 Bn |
| Apr 3, 2022 | 2.13 Bn |
| Apr 3, 2022 | 2.13 Bn |
| Oct 3, 2021 | 1.00 Mn |
| Oct 3, 2021 | 1.00 Mn |
| Jul 4, 2021 | 450.00 Mn |
| Jul 4, 2021 | 450.00 Mn |
| Apr 4, 2021 | 1.00 Bn |
| Apr 4, 2021 | 1.00 Bn |